Breast Mass, Skin Nodules

The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.

In the third episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss the challenges of expanded breast cancer screening amid a backdrop of radiologist shortages and ever-increasing volume on radiology worklists.

The only ultrasound enhancing agent that does not contain polyethylene glycol, Optison may now be utilized to enhance echocardiogram assessment of ventricular function in pediatric patients.

In the second episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss recent studies published by the Journal of the American Medical Association (JAMA) that suggested moving to more of a risk-adapted model for mammography screening.

For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.

In comparison to minimal or mild background parenchymal enhancement on contrast-enhanced mammography (CEM), researchers found that moderate or marked BPE was associated with a 12 percent lower AUC for breast cancer detection.